Clinical Trial Update: Triple Antimalarial Combination to Accelerate the Parasite Clearance and to Prevent the Selection of Resistant Parasites [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating a triple antimalarial combination to speed parasite clearance and reduce emergence of resistance in drug-resistant Plasmodium …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plasmodium Falciparum Malaria

Snippet

Sponsor: Nurex S.r.l. | Conditions: Plasmodium Falciparum Malaria (Drug Resistant) | Phase 2 | Status: UNKNOWN